With novel radiopharmaceutical therapies entering clinical trials and into clinical practice, the 2025 Transatlantic Exchange in Oncology will focus on bringing together key experts from Boston, USA and Paris, France to highlight the latest advances in the application of these targeted agents for oncology. The 1-day event will deliver a comprehensive overview of this highly competitive and dynamic area within the R&D landscape, enabling attendees to understand cutting-edge research as well as the challenges in bringing these therapies to routine clinical application.
March 19, 2025
10:00 – 10:20 AM | Opening and Welcome Toni K. Choueiri, MD (Program Chair, Moderator)
Karim Fizazi, MD, PhD (Program Chair, Moderator)
Kevin Haigis, PhD
Fabrice Barlesi, MD, PhD
Patrick Therasse, MD, PhD
10:20 – 11:50 AM | Session 1
Precision Oncology & Molecular Imaging: Early Detection and Characterization
Fabrice Barlesi, MD, PhD (Moderator)
Toni K. Choueiri, MD (Moderator)
Antibody-Based Radiotheranostics for Tumor Characterization and Therapy
Fay Nicolson, PhD
Advances in Genitourinary Cancers (Lessons Learned From PSMA)
Ronan Flippot, MD
The Model of Breast Cancer: From In Vivo Target to Diagnostic Radiopharmaceutical
Théophraste Henry, PhD
Using Imaging to Test Tumor Biology and Heterogeneity
Himisha Beltran, MD
Session includes 15-min Q&A and 15-min break
11:50 – 12:30 PM | Keynote Address Fabrice André, MD, PhD (Moderator)
Heather Jacene, MD (Moderator)
Seeing Beyond VISION: Designing RLT Trials That Yield a Survival Benefit
Michael J. Morris, MD, FASCO
Session includes a 10-min Q&A
12:30 – 14:30 | Session 2
How to Go From Non-Radiolabeled Target to a Radiolabeled Active Product
Toni K. Choueiri, MD (Moderator)
Patrick Therasse, MD, PhD (Moderator)
Are My Target and Probe Suitable for Radiolabeling?
Mohammad Rashidian, PhD
Developing Targeted Alpha Therapeutics: Heartbreak or Happily Ever After?
Anthony P. Belanger, PhD
The Radiolabeled ADC: The Pharmaceutical Challenges
Angelo Paci, PharmD, PhD
The First in Human: How to Deal With Phase I Studies
Christophe Massard, MD, PhD
Session includes 15-min Q&A and 15-min break
14:30 - 16:15 – | Session 3
Future Directions and Latest Clinical Applications
Karim Fizazi, MD, PhD (Moderator)
Heather Jacene, MD (Moderator)
Monitoring and Tumor Assessment Post-Radioligand Therapy
Praful Ravi, MB, BChir, MRCP
Strategies to Target the Immune System With Radiolabeled Antibodies
Bertrand Kuhnast, PhD
The Impact of Molecular Profile on Response to Treatment: The UNLOCK Program
Yohann Loriot, MD, PhD
Radiopharmaceuticals in Heme Malignancies: Waldenström Macroglobulinemia
Jorge J. Castillo, MD
Radioconjugates Using Small Linear Peptides
Kevin Lee, PhD, MBA
Session includes 15-min Q&A and 15-min break
16:15 – 17:15 | Session 4
Radioligand Therapies: Academia and Industry Perspectives
Désirée Deandreis, MD (Moderator)
Leonhard Schaetz, MD (Moderator)
Radiopharmaceuticals – It Is All About Compromises
Amal Saidi, PhD
Challenges in Scaling Up Facilities
Désirée Deandreis, MD
Industry Perspective: Scaling Up Radio-DARPin Platform: Experience of Two European Biotech Partners - Molecular Partners and Orano Med
Michael Stumpp, PhD
Amal Saidi, PhD
Session includes 15-min Q&A and 15-min break
17:15 - 17:30 | Closing Remarks
Chairs to Close
Toni K. Choueiri, MD (Program Chair, Moderator)
Karim Fizazi, MD, PhD (Program Chair, Moderator)